Skip to main content

Table 2 Meta-regression of change in AUC of C-peptide (two factors)

From: Anti-CD3 monoclonal antibody in treating patients with type 1 diabetes: an updated systematic review and meta-analysis

Variables

β (95% CI)

P

R2

Model 1: cumulative dose combined with age

95.4

 Dose ≥ 25 mg

0.499 (0.221, 0.777)

 < 0.001

 

 Average age

− 0.023 (− 0.052, 0.006)

0.113

 

Model 2: cumulative dose combined with T1D diagnosis duration

89.4

 Dose ≥ 25 mg

0.548 (0.217, 0.879)

0.001

 

 T1D diagnosis duration ≤ 6 weeks, yes

0.133 (− 0.229, 0.496)

0.470

 
  1. AUC Area under the curve, CI Confidence interval, T1D Type 1 diabetes.